Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | LPL | P06858 | 3/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17801283 | 0.87 | FFAR1 (0.46) | FFAR1LPLLIPGIRAK4 | |
| SCHEMBL30682960 | 0.86 | FFAR1 (0.39) | FFAR1 | |
| SCHEMBL17801201 | 0.82 | FFAR1 (0.45) | FFAR1LPLLIPG | |
| SCHEMBL875957 | 0.82 | FFAR1 (0.51) | FFAR1LPLLIPGIRAK4 | |
| SCHEMBL30682976 | 0.81 | USP30 (0.49) | FFAR1 | |
| SCHEMBL17815970 | 0.80 | FFAR1 (0.50) | FFAR1LPLLIPGIRAK4 | |
| SCHEMBL19713715 | 0.80 | FFAR1 (0.50) | FFAR1LPLLIPGIRAK4 | |
| SCHEMBL24247137 | 0.79 | FFAR1 (0.42) | FFAR1 | |
| SCHEMBL24247145 | 0.79 | FFAR1 (0.42) | FFAR1 | |
| SCHEMBL16100537 | 0.79 | CREBBP (0.48) | FFAR1LPLLIPGIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12239630-B2 | Carboxylic acid aromatic amides as antagonists of bradykinin B1 receptor | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-03-04 | — | — | US | disclosed |
| US-12023319-B2 | Carboxylic acid aromatic amides | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-07-02 | — | — | US | disclosed |
| US-12023319-B2 | Carboxylic acid aromatic amides | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-07-02 | — | — | US | disclosed |
| US-11958861-B2 | Spirocyclic lactams as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2024-04-16 | — | — | US | disclosed |
| US-11905270-B2 | Carboxylic acid aromatic amides as antagonists of bradykinin B1 receptor | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-02-20 | — | — | US | disclosed |
| EP-4298099-A1 | SPIROCYCLIC LACTAMS AS JAK2 V617F INHIBITORS | Incyte Corporation (US) | 2024-01-03 | — | — | EP | disclosed |
| CN-115073421-B | Carboxylic aromatic amides as bradykinin B1 receptor antagonists | 拜耳制药股份公司 | 2023-12-19 | — | — | CN | disclosed |
| US-20230271931-A1 | CARBOXYLIC ACID AROMATIC AMIDES AS ANTAGONISTS OF BRADYKININ B1 RECEPTOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-08-31 | — | — | US | disclosed |
| US-20230271931-A1 | CARBOXYLIC ACID AROMATIC AMIDES AS ANTAGONISTS OF BRADYKININ B1 RECEPTOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-08-31 | — | — | US | disclosed |
| US-20230271931-A1 | CARBOXYLIC ACID AROMATIC AMIDES AS ANTAGONISTS OF BRADYKININ B1 RECEPTOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-08-31 | — | — | US | disclosed |
| WO-2022182839-A1 | SPIROCYCLIC LACTAMS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION (US) | 2022-09-01 | — | — | WO | disclosed |
| CN-110325523-B | Carboxylic acid aromatic amides as bradykinin B1 receptor antagonists | 拜耳制药股份公司 | 2022-07-26 | — | — | CN | disclosed |
| EP-3558960-B1 | CARBOXYLIC ACID AROMATIC AMIDES AS ANTAGONISTS OF BRADYKININ B1 RECEPTOR | Bayer Pharma AG (DE) | 2022-01-05 | — | — | EP | disclosed |
| EP-3390387-B1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | Bayer Pharma AG (DE) | 2021-11-17 | — | — | EP | disclosed |
| US-10894784-B2 | Heteroarylbenzimidazole compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-01-19 | — | — | US | disclosed |
| US-10894784-B2 | Heteroarylbenzimidazole compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-01-19 | — | — | US | disclosed |
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-02-14 | — | — | US | disclosed |
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-02-14 | — | — | US | disclosed |
| EP-3390387-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | Bayer Pharma Aktiengesellschaft (DE) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017102091-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905270-B2 | Carboxylic acid aromatic amides as antagonists of bradykinin B1 receptor | BDKRB1, BDKRB2, HCAR1 | FFAR1 74/4885LPL 4375/4885LIPG 1720/4885 |
| US-11958861-B2 | Spirocyclic lactams as JAK2 V617F inhibitors | JAK2, JAK1, STAT5A | FFAR1 4800/4885LPL 3700/4885LIPG 4071/4885 |
| US-12023319-B2 | Carboxylic acid aromatic amides | DDC, PAH, NAT1 | FFAR1 507/4885LPL 4127/4885LIPG 2020/4885 |
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | CCNI, CCNT2, CDK2 | FFAR1 3190/4885LPL 3470/4885LIPG 2413/4885 |
| US-12239630-B2 | Carboxylic acid aromatic amides as antagonists of bradykinin B1 receptor | BDKRB1, BDKRB2, HCAR1 | FFAR1 68/4885LPL 4356/4885LIPG 1582/4885 |
| US-10894784-B2 | Heteroarylbenzimidazole compounds | CCNI, CCNT2, CDK2 | FFAR1 3190/4885LPL 3470/4885LIPG 2413/4885 |
| US-20230271931-A1 | CARBOXYLIC ACID AROMATIC AMIDES AS ANTAGONISTS OF BRADYKININ B1 RECEPTOR | BDKRB1, BDKRB2, HCAR1 | FFAR1 68/4885LPL 4356/4885LIPG 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.